Original Article by Kabelo Khumalo | Business Day | 18 September 2026
Sanlam has written its AfroCentric stake down to nil after the Bonitas exit but rules out a sale, betting it can revive the business.
Image | Timon Schneider | Dreamstime.com
Sanlam has written down its investment in healthcare management group AfroCentric to nil after medical scheme Bonitas moved to end its relationship. Yet, the insurer insists there is still value to extract. The stake will stay. Sanlam CEO Paul Hanratty ruled out any sale.
Sanlam owns 60% of AfroCentric, a holding it took three years ago and which has so far proved underwhelming.
GLP-1 medicines alone can’t solve SA’s diabetes crisis, experts warn, urging earlier screening, coordinated care and better food access.
Read more...
Aspen Pharmacare’s turnaround now hinges on its sterile manufacturing, the costly network of injectable-drug plants it must fill. This follows last year’s collapse of a major mRNA contract. CEO Stephen Saad sums up the setback with a farmer’s phrase: “We lost the milk but not the cow.” The contract’s loss blew roughly R2bn out of […]
Read more...
The US healthcare affordability crisis is squeezing small employers the hardest, a mirror for local medical scheme debates.
Read more...